InflaRx (IFRX) Net Income (2016 - 2026)
InflaRx (IFRX) posted Net Income of -$6.5 million for Q1 2026, up 47.15% sequentially from -$12.4 million in Q4 2025, and up 25.13% YoY from -$5.2 million in Q1 2025.
InflaRx (IFRX) Net Income (2016 - 2026) Analysis & Trends
InflaRx has reported Net Income for 11 years, with the latest figure at -$6.5 million in Q1 2026.
- Quarterly Net Income rose 25.13% year-over-year to -$6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$51.3 million (down 4.04% YoY) and the FY2025 annual result came in at -$51.6 million, down 3.41% from the prior year.
- Net Income advanced to -$6.5 million in Q1 2026 per IFRX's latest filing, from -$12.4 million in the prior quarter.
- Over five years, Net Income peaked at $35.7 million in Q2 2024 and troughed at -$70.8 million in Q3 2024.
- A 5-year average of -$11.0 million and a median of -$10.5 million in 2024 frame the typical range for Net Income.
- The sharpest annual moves came in 2024 and 2025: Net Income soared 68.13% in 2024, then sank 126.79% in 2025.
- Over 5 years, Net Income stood at -$8.2 million in 2022, then slumped by 109.31% to -$17.1 million in 2023, then jumped by 68.13% to -$5.5 million in 2024, then tumbled by 126.79% to -$12.4 million in 2025, then jumped by 47.15% to -$6.5 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$6.5 million, -$12.4 million, and -$67.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | -12.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.55 Mn |
| Dec 31, 2025 | -12.39 Mn |
| Sep 30, 2025 | -67.48 Mn |
| Jun 30, 2025 | 35.14 Mn |
| Mar 31, 2025 | -8.75 Mn |
| Dec 31, 2024 | -5.46 Mn |
| Sep 30, 2024 | -70.79 Mn |
| Jun 30, 2024 | 35.71 Mn |
| Mar 31, 2024 | -10.49 Mn |
| Dec 31, 2023 | -17.14 Mn |
| Sep 30, 2023 | -50.10 Mn |
| Jun 30, 2023 | 33.07 Mn |
| Mar 31, 2023 | -11.90 Mn |
| Dec 31, 2022 | -8.19 Mn |
| Sep 30, 2022 | -35.28 Mn |
| Jun 30, 2022 | 29.39 Mn |
| Mar 31, 2022 | -15.72 Mn |
| Dec 31, 2021 | -14.49 Mn |
| Sep 30, 2021 | -63.53 Mn |
| Jun 30, 2021 | 32.55 Mn |